Close



Jun 1, 2023 07:00AM
Jun 1, 2023 07:00AM
Mar 27, 2023 05:02PM
Mar 27, 2023 05:00PM
Mar 27, 2023 05:00PM
Oct 5, 2022 08:00AM
Oct 5, 2022 08:00AM Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis
Mar 24, 2022 08:00AM
Mar 24, 2022 08:00AM
Feb 15, 2022 08:05AM
Feb 15, 2022 08:05AM
Feb 15, 2022 08:05AM
Nov 12, 2021 08:00AM
Nov 12, 2021 08:00AM Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments
Oct 27, 2021 08:05AM
Oct 27, 2021 08:05AM
Aug 12, 2021 08:00AM
Aug 12, 2021 08:00AM
Aug 5, 2021 08:00AM
Aug 5, 2021 08:00AM
Aug 3, 2021 08:12AM Monopar Therapeutics (MNPR) Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
Aug 3, 2021 08:00AM
Aug 3, 2021 08:00AM
May 26, 2021 08:07AM
May 26, 2021 08:00AM
May 26, 2021 08:00AM
May 24, 2021 08:09AM
May 24, 2021 08:00AM Monopar and NorthStar Announce Patent Filing on Promising Radiopharmaceutical Discovery
May 24, 2021 08:00AM
May 13, 2021 04:42PM
May 13, 2021 04:42PM
Apr 13, 2021 08:00AM
Mar 25, 2021 08:00AM
Mar 25, 2021 08:00AM
Feb 16, 2021 07:30AM Monopar Announces First Patient Dosed in its Phase 2b/3 VOICE Trial Evaluating Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
Dec 22, 2020 08:32AM
Dec 22, 2020 08:30AM
Dec 22, 2020 08:30AM
Dec 10, 2020 08:36AM
Dec 10, 2020 08:30AM
Dec 10, 2020 08:30AM
Dec 8, 2020 08:30AM Monopar Announces Initiation of its Phase 2b/3 (VOICE) Trial to Evaluate Validive® for the Prevention of Chemoradiotherapy-Induced Severe Oral Mucositis (SOM) in Oropharyngeal Cancer (OPC)
Dec 8, 2020 08:30AM
Nov 12, 2020 09:15AM
Nov 12, 2020 09:15AM
Nov 9, 2020 08:34AM
Nov 9, 2020 08:30AM
Nov 9, 2020 08:30AM
Sep 9, 2020 08:30AM Monopar and NorthStar Collaborating with Texas Lung Injury Institute for Testing of Novel Potential Therapeutic for Severe COVID-19
Sep 9, 2020 08:30AM

251,413 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All